Cargando…
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
PURPOSE: Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and fibroblast growth factor receptor (FGFR)....
Autores principales: | Choi, Yoon Ji, Kim, Hye Sook, Park, Se Hoon, Kim, Bong-Seog, Kim, Kyoung Ha, Lee, Hyo Jin, Song, Hong Suk, Shin, Dong-Yeop, Lee, Ha Young, Kim, Hoon-Gu, Lee, Kyung Hee, Lee, Jae Lyun, Park, Kyong Hwa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192917/ https://www.ncbi.nlm.nih.gov/pubmed/29334610 http://dx.doi.org/10.4143/crt.2017.438 |
Ejemplares similares
-
Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node‐positive bladder cancer: A retrospective analysis: KCSG GU 17‐03
por: Bae, Woo Kyun, et al.
Publicado: (2019) -
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
por: Kim, M., et al.
Publicado: (2023) -
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
por: Kang, Eun Joo, et al.
Publicado: (2022) -
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020) -
Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2023)